Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".
The company said the decision was made by mutual agreement with the board and that it was searching for a successor for Lars Fruergaard Jorgensen.
